Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies

被引：36

作者：

Lau, George ^{[2
]}

Marcellin, Patrick ^{[3
,4
]}

Peters, Marion ^{[1
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China

[3] Hop Beaujon, Serv Hepatol, INSERM 481, Clichy, France

[4] Hop Beaujon, Serv Hepatol, Ctr Rech Claude Bernaud Hepatite Virales, Clichy, France

来源：

HEPATOLOGY INTERNATIONAL | 2007年 / 1卷 / 02期

关键词：

treatment options; patient selection; immunomodulatory therapy; antivirals; sustained versus maintained response;

D O I：

10.1007/s12072-007-9006-5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Chronic hepatitis B virus infection, a major cause of end-stage liver disease and hepatocellular carcinoma, is a worldwide health concern. While the past two decades have brought major advances in the availability of treatments to help delay or prevent these outcomes, treatment of chronic hepatitis B remains a serious challenge, not least due to the ability of the virus to remain in hepatocyte nuclei as a source of potential reactivation-hence the term chronic hepatitis B infection. This article reviews the current treatments available and suggests a framework for a rational approach to managing the disease.

引用

页码：316 / 325

页数：10

共 67 条

[1]

Epidemiology of hepatitis B virus and genotype [J].

Allain, JP .

JOURNAL OF CLINICAL VIROLOGY, 2006, 36 :S12-S17

[2]

[Anonymous], HEP B WHO FACT SHEET

[3]

Long term effect of alpha interferon in children with chronic hepatitis B [J].

Bortolotti, F ;

Jara, P ;

Barbera, C ;

Gregorio, GV ;

Vegnente, A ;

Zancan, L ;

Hierro, L ;

Crivellaro, C ;

Vergani, GM ;

Iorio, R ;

Pace, M ;

Con, P ;

Gatta, A .

GUT, 2000, 46 (05) :715-718

[4]

Bzowej N, 2006, GASTROENTEROLOGY, V130, pA765

[5]

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B [J].

Chang, TT ;

Gish, RG ;

de Man, R ;

Gadano, A ;

Sollano, J ;

Chao, YC ;

Lok, AS ;

Han, KH ;

Goodman, Z ;

Zhu, J ;

Cross, A ;

DeHertogh, D ;

Wilber, R ;

Colonno, R ;

Apelian, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1001-1010

[6]

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].

Chen, CJ ;

Yang, HI ;

Su, J ;

Jen, CL ;

You, SL ;

Lu, SN ;

Huang, GT ;

Iloeje, UH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73

[7]

Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study [J].

Chen, G ;

Lin, WY ;

Shen, FM ;

Iloeje, UH ;

London, WT ;

Evans, AA .

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2005, 34 (01) :132-137

[8]

Hepatitis B virus genotypes in the United States: Results of a nationwide study [J].

Chu, CJ ;

Keeffe, EB ;

Han, SH ;

Perrillo, RP ;

Min, AD ;

Soldevila-Pico, C ;

Carey, W ;

Brown, RS ;

Luketic, VA ;

Terrault, N ;

Lok, ASF .

GASTROENTEROLOGY, 2003, 125 (02) :444-451

[9]

Entecavir resistance is rare in nucleoside naive patients with hepatitis B [J].

Colonno, Richard J. ;

Rose, Ronald ;

Baldick, Carl J. ;

Levine, Steven ;

Pokornowski, Kevin ;

Yu, Cheng F. ;

Walsh, Ann ;

Fang, Jie ;

Hsu, Mayla ;

Mazzucco, Charles ;

Eggers, Betsy ;

Zhang, Sharon ;

Plym, Mary ;

Klesczewski, Kenneth ;

Tenney, Daniel J. .

HEPATOLOGY, 2006, 44 (06) :1656-1665

[10]

Peginterferon α-2a (40 kDa):: an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B [J].

Cooksley, WGE ;

Piratvisuth, T ;

Lee, SD ;

Mahachai, V ;

Chao, YC ;

Tanwandee, T ;

Chutaputti, A ;

Chang, WY ;

Zahm, FE ;

Pluck, N .

JOURNAL OF VIRAL HEPATITIS, 2003, 10 (04) :298-305

← 1 2 3 4 5 6 7 →